Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: a Southwest Oncology Group Study.
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000633:toxicity*; D001088:Arabinonucleotides / Q000633:toxicity*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D001084:Vidarabine Phosphate / Q000031:analogs & derivatives / Q000627:therapeutic use / Q000633:toxicity*
D000903:Antibiotics, Antineoplastic; D001088:Arabinonucleotides; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate